Bio-Rad raises 2025 life science guidance to flat to 1% growth and expands ddPCR portfolio following Stilla acquisition
Source: SeekingAlpha
2025-07-31 21:56:05 ET
More on Bio-Rad Laboratories, Inc.
- Bio-Rad Laboratories, Inc. (BIO) Q2 2025 Earnings Call Transcript
- Bio-Rad Laboratories, Inc. 2025 Q2 - Results - Earnings Call Presentation
- Bio-Rad: With Low Debt And A Stock Price Drop, Is The Company Undervalued?
- Bio-Rad Laboratories, Inc. Non-GAAP EPS of $2.61 beats by $0.86, revenue of $651.6M beats by $37.31M
- Bio-Rad Laboratories, Inc. Q2 2025 Earnings Preview
Read the full article on Seeking Alpha
For further details see:
Bio-Rad raises 2025 life science guidance to flat to 1% growth and expands ddPCR portfolio following Stilla acquisition
Bio-Rad Laboratories Inc. Class A
NASDAQ: BIO
BIO Trading
11.5% G/L:
$277.42 Last:
471,754 Volume:
$274.72 Open:
BIO Latest News
BIO Stock Data
$8,088,674,023
21,121,296
0.01%
179
N/A
Biotechnology & Life Sciences
Healthcare
US
Hercules
